[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349705-105":59,"doc-detail-349705-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-phase-iii-study-of-perioperative-dostarlimab-in-patients-with-dmmrmsi-h-resectable-colon-cancer-azur-2-study-design","A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design","","The role of perioperative immunotherapy as a chemotherapy-free option for patients with resectable mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer is evolving, with early-phase neoadjuvant studies reporting favorable long-term outcomes. AZUR-2 is an ongoing global Phase III open-label randomized study comparing perioperative dostarlimab monotherapy with standard of care in adults with previously untreated, pathologically confirmed, radiologically evaluable T4N0 or Stage III resectable dMMR/MSI-H colon adenocarcinoma. Patients are randomized 2:1 to neoadjuvant dostarlimab, surgery, and adjuvant dostarlimab versus immediate surgery with standard of care. Event-free survival is the primary endpoint and overall survival and key secondary measures include pathological response, safety, and tolerability.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-phase-iii-study-of-perioperative-dostarlimab-in-patients-with-dmmrmsi-h-resectable-colon-cancer-azur-2-study-design/349705/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-phase-iii-study-of-perioperative-dostarlimab-in-patients-with-dmmrmsi-h-resectable-colon-cancer-azur-2-study-design/349705.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the AZUR-2 study evaluating?","Question",{"text":113,"@type":114},"AZUR-2 evaluates perioperative dostarlimab monotherapy versus standard of care for adults with resectable dMMR/MSI-H colon cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are participants assigned to treatment arms?",{"text":118,"@type":114},"Participants are randomized 2:1 either to receive neoadjuvant dostarlimab, surgery, then adjuvant dostarlimab, or to have immediate surgery followed by standard of care.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the primary endpoint of the study?",{"text":122,"@type":114},"The primary endpoint is event-free survival assessed by blinded independent central review.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349705,1790380221,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":8,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 2, 137–145  \n[https://doi.org/10.1080/14796694.2025.2606910](https://doi.org/10.1080/14796694.2025.2606910)  \nCLINICAL TRIAL PROTOCOL  \nA Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design  \nNaureen Starling a, Elena Elez b, John H. Strickler c, Al Benson d, Eiji Oki e, Guillermo Mendezf, Reyes Ferreirog, Yong Loo Lau h, Akihito Kawazoe i, Min Tianj, Nicole Campbellk, Daniel N. Cohen j, Ken Edwardsl, Neda Stjepanovicm and Jenny F. Seligmann n  \naGastrointestinal and Lymphoma Unit, Royal Marsden, London, UK; bMedical Oncology Department, Vall d’Hebron Hospital, Barcelona, Spain; cDivision of Medical Oncology, Duke Cancer Institute, Durham, NC, USA; dRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; e Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; fHospital Universitario Fundaciòn Favaloro, Buenos Aires, Argentina; gRamón y Cajal Hospital, Madrid, Spain; hHemato-Oncologia de Panama Especializada, Panama City, Panama; iDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; jOncology Clinical Development, GSK, Collegeville, PA, USA; kOncology Clinical Development, GSK, Toronto, Canada; lOncology Clinical Development, GSK, Stevenage, UK; mOncology Clinical Development, GSK, Baar, Switzerland; n Leeds Institute of Medical Research, University of Leeds, Leeds, UK  \nABSTRACT  \nThe role of perioperative immunotherapy as a chemotherapy-free option for patients with resectable mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer is evolving, with early-phase neoadjuvant studies reporting favorable long-term outcomes. AZUR-2 is an ongoing global, Phase III, open-label, randomized study evaluating the efficacy of perioperative dostarlimab monotherapy compared with standard of care (SoC) (adjuvant chemotherapy or surveillance) in adult patients with previously untreated, pathologically confirmed, radiologically evaluable T4N0 or Stage III resectabledMMR/MSIH colon adenocarcinoma. Patients will be randomized 2:1 to receive neoadjuvant dostarlimab 500 mg every 3 weeks (4 cycles), followed by surgery, then adjuvant dostarlimab 1000 mg every 6 weeks (6 cycles), or to receive immediate surgery followed by SoC. The primary endpoint is event-free survival assessed by blinded independent central review. The key secondary endpoint is overall survival; additional secondary endpoints include pathological response assessed by residual viable tumor determined by local assessment, safety, and tolerability.  \nClinical trial registration: NCT05855200 ([www.clinicaltrials.gov](www.clinicaltrials.gov)).  \nPLAIN LANGUAGE SUMMARY  \nWhat is the purpose of the study?  \nResearchers are trying to find better ways of treating colon cancers that have spread beyond the colonto nearby tissues (also known as “advanced” colon cancer) . There are different kinds of colon cancer and one type is called mismatch repair deficient, or dMMR for short. This means that the cancer cells have a faulty gene repair system.  \nImmunotherapy works by helping the immune system to recognize and kill cancer cells. Immunotherapy is more effective than chemotherapy in patients with advanced dMMR colon and rectal cancer that is not suitable for surgery. Researchers would like to know whether immunotherapy will also deliver better outcomes than chemotherapy for patients with dMMR colon cancer undergoing surgery.  \nWhat will the study look at?  \nAZUR-2 is an ongoing clinical study in adults with previously untreated advanced dMMR colon cancer that is suitable for surgery. The study will divide approximately 711 patients into two groups. One group will be treated with an immunotherapy drug called dostarlimab, then undergo surgery, then continue with dostarlimab.  \nThe other group will be treated using the typical approach used","cbCaieMn16WTBV3K","https://ap.wps.com/l/cbCaieMn16WTBV3K","pdf",818869,"English","# Introduction\n# Clinical Trial Protocol\n## Study Design and Randomization\n## Endpoints and Assessments","[{\"question\":\"What is the AZUR-2 study evaluating?\",\"answer\":\"AZUR-2 evaluates perioperative dostarlimab monotherapy versus standard of care for adults with resectable dMMR/MSI-H colon cancer.\"},{\"question\":\"How are participants assigned to treatment arms?\",\"answer\":\"Participants are randomized 2:1 either to receive neoadjuvant dostarlimab, surgery, then adjuvant dostarlimab, or to have immediate surgery followed by standard of care.\"},{\"question\":\"What is the primary endpoint of the study?\",\"answer\":\"The primary endpoint is event-free survival assessed by blinded independent central review.\"}]","A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design | PDF",1790085130,23,[147],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/20c3ea5b88f5afdedb226cbb5bcaea17.webp",983,1280]